{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000033","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.459789+00:00","generated_at":"2026-05-17T20:28:02.703317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Halozyme Q2 revenue $326M (+41% YoY); raises FY25 guidance, files patent suit vs Merck","bullets":["Q2 total revenue $325.7M (+41% YoY); royalty revenue $205.6M (+65% YoY).","GAAP diluted EPS $1.33 (+85% YoY); Non-GAAP diluted EPS $1.54 (+69% YoY).","Raises 2025 total revenue guidance to $1.275-1.355B (26-33% YoY) and Non-GAAP EPS to $6.00-6.40.","Completed $303M share repurchases in Q2; initiated third $250M tranche under $750M program.","Filed patent infringement lawsuit against Merck alleging unauthorized use of MDASE technology for SC Keytruda."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000033","json":"https://secwatch.observer/filing/0001159036-25-000033.json","markdown":"https://secwatch.observer/filing/0001159036-25-000033.md","text":"https://secwatch.observer/filing/0001159036-25-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/0001159036-25-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/halo-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:28:02.703317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}